Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

Reviva Pharmaceuticals Holdi / Equity Bottom-Up

<ul><li>Reviva is a research and development pharmaceutical company with two portfolio compounds targeting nine indications.</li><li>The candidates address multiple related mental disorders, rare diseases & other categories of un met need.</li><li>Reviva's lead indication in schizophrenia with brilaroxazine (RP5063) completed its 1st Phase III trial & is set to begin its 2nd in 1Q25.</li></ul>

Reviva is a research and development pharmaceutical company with two portfolio compounds targeting nine indications.The candidates address multiple related mental disorders, rare diseases & other categories of un met need.Reviva's lead indication in schizophrenia with brilaroxazine (RP5063) completed its 1st Phase III trial & is set to begin its 2nd in 1Q25.

<ul><li>Reviva is a research and development pharmaceutical company with two portfolio compounds targeting nine indications.</li><li>The candidates address multiple related mental disorders, rare diseases & other categories of un met need.</li><li>Reviva's lead indication in schizophrenia with brilaroxazine (RP5063) completed its 1st Phase III trial & expects to begin its 2nd in 2025.</li></ul>

Reviva is a research and development pharmaceutical company with two portfolio compounds targeting nine indications.The candidates address multiple related mental disorders, rare diseases & other categories of un met need.Reviva's lead indication in schizophrenia with brilaroxazine (RP5063) completed its 1st Phase III trial & expects to begin its 2nd in 2025.

<ul><li>Reviva is a research and development pharmaceutical company with two portfolio compounds targeting nine indications.</li><li>The candidates address multiple related mental disorders, rare diseases & other categories of un met need.</li><li>Reviva's lead indication in schizophrenia with brilaroxazine (RP5063) completed its 1st Phase III trial & began its 2nd in 2Q:24.</li></ul>

Reviva is a research and development pharmaceutical company with two portfolio compounds targeting nine indications.The candidates address multiple related mental disorders, rare diseases & other categories of un met need.Reviva's lead indication in schizophrenia with brilaroxazine (RP5063) completed its 1st Phase III trial & began its 2nd in 2Q:24.

United States

Reviva Pharmaceuticals Holdings, Inc. operates as a clinical development pharmaceutical company. The Company focuses on developing a portfolio of internally discovered therapies that address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases. Reviva Pharmaceuticals Holdings serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Reviva Pharmaceuticals Holdi (RVPH US)

RVPH: Preliminary OLE Readout

Reviva is a research and development pharmaceutical company with two portfolio compounds targeting nine indications. The candidates address...

Zacks Small Cap Research

RVPH: Year-End OLE Update

Reviva is a research and development pharmaceutical company with two portfolio compounds targeting nine indications. The candidates address...

Zacks Small Cap Research

RVPH: August OLE Update

Reviva is a research and development pharmaceutical company with two portfolio compounds targeting nine indications. The candidates address...

Zacks Small Cap Research

RVPH: Enrollment Right Around the Corner

Reviva is a research and development pharmaceutical company with two portfolio compounds targeting nine indications. The candidates address...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)